Angiotensin II receptor blocker combinations: From guidelines to clinical practice

References

• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1153.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, . Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–2158.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923–934.
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, . Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304: 61–68.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Wang YR, Alexander GC and Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141–147.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, . Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–661.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, . Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393–404.
   PubMedGoogle Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, Bestwick JP and Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK and Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
   PubMed Web of Science ®Google Scholar
• Erdine S. Compliance with the treatment of hypertension: The potential of combination therapy. J Clin Hypertens (Greenwich). 2010;12:40–46.
   PubMed Web of Science ®Google Scholar
• Krousel-Wood M, Thomas S, Muntner P and Morisky D. Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357–362.
   PubMed Web of Science ®Google Scholar
• Schroeder K, Fahey T and Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722–732.
   PubMed Web of Science ®Google Scholar
• WHO. Adherence to long-term therapies: Evidence for action. http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. 2003. Accessed: 21 September 2010.
   Google Scholar
• Claxton AJ, Cramer J and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S and Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension. 2010;55:399–407.
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, Fernandez V and Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010; 32:1252–1269.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourciere Y, Chiang YT and Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial. Hypertension. 2009;54:32–39.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366: 895–906.
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, . Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370: 829–840.
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, . Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022–2031.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, . A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805–2816.
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK and Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ. 2003;326: 1427.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P and Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624–1630.
   PubMed Web of Science ®Google Scholar
• Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin–angiotensin system in the hypertension paradigm. Clin Exp Hypertens [Research Support, Non-U.S. Gov't Review]. 2010;32:35–42.
   Google Scholar
• Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: A review of the factorial-design studies. J Clin Hypertens [Research Support, Non-U.S. Gov't Review]. 2004;6:569–577.
   Google Scholar
• Ram CV. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: A review of factorial-design studies. Current medical research and opinion [Review]. 2009;25:177–185.
   PubMed Web of Science ®Google Scholar
• Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M and Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther. 2002;71:68–76.
   PubMed Web of Science ®Google Scholar
• Coltamai L, Maillard M, Simon A, Vogt B and Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens. 2010;28:520–526.
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999;33:850–855.
   PubMed Web of Science ®Google Scholar
• Fabia MJ, Abdilla N, Oltra R, Fernandez C and Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25: 1327–1336.
   PubMed Web of Science ®Google Scholar
• Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR and Burnier M. Sustained 24-hour blockade of the renin– angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther. 2005; 78:501–507.
   PubMed Web of Science ®Google Scholar
• Jones MR, Sealey JE and Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. American Journal of Hypertension. 2007;20:907–916.
   PubMed Web of Science ®Google Scholar
• Smith DH, Dubiel R and Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41–50.
   PubMedGoogle Scholar
• Brunner HR, Stumpe KO and Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23:419–430.
   PubMed Web of Science ®Google Scholar
• Neutel JM. Prescribing patterns in hypertension: The emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Current Med Res Opin [Research Support, Non-U.S. Gov't Review]. 2008;24:2389–2401.
   PubMed Web of Science ®Google Scholar
• Fogari R, Taddei S, Holm-Bentzen M, Baszak J, Melani L and Schumacher K. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: A randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin Drug Investig. 2010;30:581–597.
   PubMed Web of Science ®Google Scholar
• Oparil S, Chrysant SG, Kereiakes D, Xu J, Chavanu KJ, Waverczak W, . Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich). 2008;10:911–921.
   PubMed Web of Science ®Google Scholar
• Volpe M, Brommer P, Haag U and Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009; 29:11–25.
   PubMed Web of Science ®Google Scholar
• Rump LC and Sellin L. Combination therapy for hypertension: Focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Expert Opin Pharmacother. 2010;11: 2231–2242.
   PubMed Web of Science ®Google Scholar
• Chrysant S, Melino M, Karki S, Lee J and Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604.
   PubMed Web of Science ®Google Scholar
• Heagerty AM, Laeis P and Haag U. Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy – additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens. 2009;27 Suppl 4 S283.
   Google Scholar
• Chrysant SG, Weber MA, Wang AC and Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17:252–259.
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chavanu KJ and Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: Secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9:241–251.
   PubMedGoogle Scholar
• Rump LC, Girerd X, Sellin L and Stegbauer J. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens. 2010;Epub ahead of print.
   Google Scholar
• Kereiakes DJ, Neutel J, Stoakes KA, Waverczak WF, Xu J, Shojaee A, . The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich). 2009;11:411–421.
   PubMed Web of Science ®Google Scholar
• Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J and Shojaee A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin. 2010;26:721–728.
   PubMed Web of Science ®Google Scholar
• Punzi H, Neutel JM, Kereiakes DJ, Shojaee A, Waverczak WF, Dubiel R, . Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4:209–221.
   PubMedGoogle Scholar
• Ram VS, Sachson RA, Qian C, Patel M and Stoakes KA. Effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension, type 2 diabetes, and metabolic syndrome. J Clin Hypertens. 2010;12:A96.
   Google Scholar
• Haller H, Ito S, Izzo JL, Jr., Januszewicz A, Katayama S, Menne J, . Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med. 2011;364:907–917.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events. http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm; 2011.
   Google Scholar
• Chrysant S, Melino M, Fernandez V, Lee J and Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension: Analysis by age and gender. J Clin Hypertens. 2010;12Suppl 1:A30–A31.
   Google Scholar
• Izzo J, Melino M, Fernandez V, Lee J and Heyrman R. 24-hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide. J Clin Hypertens. 2010;12 Suppl 1:A34–A35.
   Google Scholar
• Ram CV, Sachson R, Littlejohn T, Qian C, Shojaee A, Stoakes KA, . Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol. 2011;107:1346–1352.
   PubMedGoogle Scholar
• Weir MR, Hsueh W, Nesbitt SD, Littlejohn TJ, Graff A, Shojaee A, . A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide. J Clin Hypertens. 2011;Published ahead of print (5 FEB 2011, DOI: 10.1111/j.1751-7176.2011.00437).
   Google Scholar